Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Express Scripts
Boehringer Ingelheim
Baxter
Dow

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,673,838

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,673,838 protect, and when does it expire?

Patent 6,673,838 protects PRISTIQ and is included in one NDA.

This patent has forty-six patent family members in thirty-one countries.

Summary for Patent: 6,673,838
Title: Succinate salt of O-desmethyl-venlafaxine
Abstract:A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
Inventor(s): Hadfield; Anthony F. (Nanuet, NY), Shah; Syed M. (East Hanover, NJ), Winkley; Michael W. (Campbell Hall, NY), Sutherland; Karen W. (New City, NY), Provost; James A. (Waltham Chase, GB), Park; Aeri (West Lafayette, IN), Shipplett; Rex A. (Wolcott, IN), Russell; Brenton W. (West Lafayette, IN), Weber; Beat T. (Zofingen, CH)
Assignee: Wyeth (Madison, NJ)
Application Number:10/073,743
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,673,838
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Formulation; Use;

Drugs Protected by US Patent 6,673,838

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial Y FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No   Start Trial   Start Trial Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes   Start Trial   Start Trial Y MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Boehringer Ingelheim
Dow
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.